Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All curcumin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization time 29% Improvement Relative Risk Pulmonary involvement.. 9% no CI Curcumin  Honarkar Shafie et al.  LATE TREATMENT  DB RCT Is late treatment with curcumin beneficial for COVID-19? Double-blind RCT 44 patients in Iran Shorter hospitalization with curcumin (not stat. sig., p=0.22) c19early.org Honarkar Shafie et al., Phytotherapy R.., Jan 2022 Favors curcumin Favors control

Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial

Honarkar Shafie et al., Phytotherapy Research, doi:10.1002/ptr.7374
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
RCT 48 hospitalized patients in Iran, 24 treated with nanocurcumin, showing lower hospitalization time with treatment. The number of patients shown in Table 3 (31 and 27 for each arm) is inconsistent with the number reported as randomized to each arm (24). 160 mg/day nanocurcumin for 6 days. IRCT20131125015536N13.
This study is excluded in meta analysis: unresolved data inconsistency.
hospitalization time, 28.9% lower, relative time 0.71, p = 0.22, treatment mean 6.31 (±5.26) n=23, control mean 8.87 (±8.12) n=21.
relative pulmonary involvement score, 9.1% better, RR 0.91, treatment 23, control 21.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Honarkar Shafie et al., 12 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 10 authors.
This PaperCurcuminAll
Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID‐19: A randomized double‐blind placebo‐controlled trial
Elaheh Honarkar Shafie, Fateme Taheri, Neda Alijani, Ahmad Reza Okhovvat, Razieh Goudarzi, Nasrin Borumandnia, Leila Aghaghazvini, Seyed Mahdi Rezayat, Saeidreza Jamalimoghadamsiahkali, Mohammad Javad Hosseinzadeh‐attar
Phytotherapy Research, doi:10.1002/ptr.7374
It has been more than a year since the outbreak of COVID-19, and it is still the most critical issue of the healthcare system. Discovering effective strategies to treat infected patients is necessary to decrease the mortality rate. This study aimed to
CONFLICT OF INTEREST The authors declared no conflicts of interest.
References
Adibian, Hodaei, Nikpayam, Sohrab, Hekmatdoost et al., The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebocontrolled trial, Phytotherapy Research
Aggarwal, Harikumar, Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases, The International Journal of Biochemistry & Cell Biology
Anand, Kunnumakkara, Newman, Aggarwal, Bioavailability of curcumin: Problems and promises, Molecular Pharmaceutics
Bahrs, Kimmig, Weis, Ankert, Hagel et al., 2 point seroprevalence among hospital staff, doi:10.1111/tbed.14041
Barrett, Brown, Mundt, Safdar, Dye et al., The Wisconsin upper respiratory symptom survey is responsive, reliable, and valid, Journal of Clinical Epidemiology
Cavezzi, Troiani, Corrao, COVID-19: Hemoglobin, iron, and hypoxia beyond inflammation. A Narrative Review, Clinics and Practice
Chen, Zheng, Liu, Yan, Xu et al., Plasma CRP level is positively associated with the severity of COVID-19, Annals of Clinical Microbiology and Antimicrobials
Conti, Ronconi, Caraffa, Gallenga, Ross et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies, Journal of Biological Regulators and Homeostatic Agents
Festa, D'agostino, Jr, Howard, Mykkänen et al., Chronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS), Circulation
Gold, Sehayek, Gabrielli, Zhang, Mccusker et al., COVID-19 and comorbidities: A systematic review and meta-analysis, Postgraduate Medicine
Guay, Champagne, Guibord, Gruenwald, The Efficacy and Safety of a Patent Pending Combination of Ginger and Goldenrod Extracts on the Management of Cold Symptoms: A Randomized, Double-Blind Controlled Trial, The Efficacy and Safety of a Patent Pending Combination of Ginger and Goldenrod Extracts on the Management of Cold Symptoms: A Randomized, Double-Blind Controlled Trial
Gupta, Patchva, Aggarwal, Therapeutic roles of curcumin: Lessons learned from clinical trials, The AAPS Journal
Hewlings, Kalman, Curcumin: A review of its' effects on human health, Food
Holmes, Macfarlane, Macfarlane, Hubbard, Symptoms, signs, and prescribing for acute lower respiratory tract illness, British Journal of General Practice
Khaerunnisa, Kurniawan, Awaluddin, Suhartati, Soetjipto, Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study
Kocher, Bohnert, Schiborr, Frank, Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals, Molecular Nutrition & Food Research
Mahase, China coronavirus: mild but infectious cases may make it hard to control outbreak, report warns, BMJ, doi:10.1136/bmj.m325
Moballegh Nasery, Abadi, Poormoghadam, Zarrabi, Keyhanvar et al., Curcumin delivery mediated by biobased nanoparticles: A review, Molecules, doi:10.3390/molecules25030689
Moghadamtousi, Abdul Kadir, Hassandarvish, Tajik, Abubakar et al., Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial, Phytotherapy Research
Palmeira, Barbuto, Silva, Carneiro-Sampaio, Why is SARS-CoV-2 infection milder among children?, Clinics, doi:10.6061/clinics/2020/e1947
Pan, Ye, Sun, Gui, Liang et al., Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19), Radiology, doi:10.1148/radiol.2020200370
Panahi, Hosseini, Khalili, Naimi, Majeed et al., Antioxidant and anti-inflammatory effects of curcuminoidpiperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis, Clinical Nutrition
Pepys, Hirschfield, C-reactive protein: a critical update, The Journal of Clinical Investigation
Raut, Schein, Mody, Grant, Benson et al., Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US, Current Medical Research and Opinion
Saadati, Sadeghi, Mansour, Yari, Poustchi et al., Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial, BMC Gastroenterology, doi:10.1186/s12876-019-1055-4
Sahebkar, Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a meta-analysis, Phytotherapy Research
Salehi, Abedi, Balakrishnan, Gholamrezanezhad, Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients, American Journal of Roentgenology
Shelke, Pawar, Tripathi, Maurya, Srivasthav et al., An open label, randomized, multicenter, comparative, three arm phase II clinical study to evaluate the safety and efficacy of mixture of five species of Ocimum in subjects with acute common cold, Annals of Phytomedicine
Shiri, Sorouri, Geramifar, Nazari, Abdollahi et al., Machine learning-based prognostic modeling using clinical data and quantitative radiomic features from chest CT images in COVID-19 patients, Computers in Biology and Medicine
Stohs, Chen, Ray, Ji, Bucci et al., Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: A review, Molecules
Xie, Covassin, Fan, Singh, Gao et al., Association between hypoxemia and mortality in patients with COVID-19, Mayo Clinic Proceedings, doi:10.1016/j.mayocp.2020.04.006
Ye, Wang, Mao, Cytokine storm in COVID-19 and treatment, The Journal of Infection
Zhou, Wang, Zhu, Xia, CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China, American Journal of Roentgenology
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit